인기 연구 키워드 :
인기 활용 키워드 :

( Toshifumi Hibi )

연구자정보

- 저자 ( Toshifumi Hibi )
- 발표논문( 8)
공동연구자( 49)
유사연구자 ( 20)※활용도순 상위 20명

연구자관계도

'( Toshifumi Hibi )'의 연구자 점유율

논문점유율 요약
동일주제 총논문수	주제별 연구자 총논문수	연구자점유율(주제별 연구자점유율의 평균)
649	39	37.6%

연구자 점유율
주제		주제별 논문수	주제별 연구자논문수	주제별 연구자점유율
주제어	Endoscopic findings	1	1	100.0%
	Multimatrix	1	1	100.0%
	Budesonide foam	1	1	100.0%
	Complete mucosal healing	1	1	100.0%
	Janus kinase	1	1	100.0%
	asacol	1	1	100.0%
	ulcerative Mesalazine Mainte ...	1	1	100.0%
	ph-dependent-release mesalami ...	2	1	50.0%
	sprit(manas)	2	1	50.0%
	심·심소 차제계 기. 일심	2	1	50.0%
	CYP3A5	3	1	33.3%
	individualizedtreatment	4	1	25.0%
	5-aminosalicylicacid	5	1	20.0%
	double-blind method	5	1	20.0%
	mesalazine	6	1	16.7%
	Drug compounding	7	1	14.3%
	Mesalamine	10	1	10.0%
	Active	11	1	9.1%
	patientacceptanceofhealthcare	13	1	7.7%
	Exacerbation	16	1	6.3%
	ulcerative	172	7	4.1%
	clinical features	26	1	3.8%
	Clinical trials	28	1	3.6%
	colitis	227	8	3.5%
	Medication adherence	47	1	2.1%
	tacrolimus	56	1	1.8%
계		649	39
* 주제로 분류 되지 않은 논문건수			0

'( Toshifumi Hibi )'의 발표논문(8)

Efficacy and safety of two pH-dependent-release mesalamine doses in moderately active ulcerative colitis: a multicenter, randomized, double-blind, parallel-group study
( Toshifumi Hibi ) Mitsuo Iida Isamu Saida Hiroaki Ito ( Yasuo Suzuki ) 대한장연구학회 [2016]
Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized, double-blind study
( Akihiro Ohori ) ( Toshifumi Hibi ) ( Seiichi Mizushima ) ( Haruo Nishino ) ( Haruhiko Ogata ) ( Atsushi Hagino ) 대한장연구학회 [2017]
Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies
( Hyo Jong Kim ) ( Young Ho Kim ) ( Toshifumi Hibi ) ( Shoko Arai ) ( Satoshi Motoya ) ( Naoki Isogawa ) ( Junichi Tabira ) ( Isao Kawaguchi ) ( Hirotoshi Yuasa ) ( Dong Soo Han ) ( Mamoru Watanabe ) 대한장연구학회 [2018]
Comparison of efficacy of once daily multimatrix mesalazine 2.4 g/day and 4.8 g/day with other 5-aminosalicylic acid preparation in active ulcerative colitis: a randomized, double-blind study
( Atsushi Hagino ) ( Toshifumi Hibi ) ( Tadashi Yokoyama ) ( Seiichi Mizushima ) ( Haruhiko Ogata ) 대한장연구학회 [2018]
5-Aminosalicylic acid aggravates colitis mimicking exacerbation of ulcerative colitis
( Makoto Naganuma ) ( Yasushi Iwao ) ( Toshifumi Hibi ) ( Tomoharu Yajima ) ( Tadakazu Hisamatsu ) ( Susumu Okamoto ) ( Nagamu Inoue ) ( Katsuyoshi Matsuoka ) ( Jun Miyoshi ) ( Haruhiko Ogata ) ( Fumiaki Ueno ) ( Atsushi Yoshida ) ( Takanori Kanai ) 대한장연구학회 [2018]
Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
( Eiko Saito ) ( Toshifumi Hibi ) ( Taku Kobayashi ) ( Tadakazu Hisamatsu ) ( Shinji Okabayashi ) ( Ryo Ozaki ) ( Miki Miura ) ( Masaru Nakano ) ( Mari Hayashida ) ( Keiji Yagisawa ) ( Hajime Matsubara ) ( Takahiko Toyonaga ) 대한장연구학회 [2019]
Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis
( Eiko Saito ) ( Toshifumi Hibi ) ( Taku Kobayashi ) ( Shintaro Sagami ) ( Shinji Okabayashi ) ( Satoshi Kuronuma ) ( Ryo Ozaki ) ( Osamu Takeuchi ) ( Masaru Nakano ) ( Keiji Yagisawa ) ( Junichi Tanaka ) ( Takahiko Toyonaga ) 대한장연구학회 [2019]
Predictive factors for achievement of mucosal healing by budesonide 2-mg foam in ulcerative colitis: a pooled analysis of data from two clinical trials
( Eisei Oda ) ( Toshifumi Hibi ) ( Yoshitomo Chujoh ) ( Yoji Yamada ) ( Ryoichi Yoshihara ) ( Mamoru Watanabe ) ( Makoto Naganuma ) 대한장연구학회 [2020]

( Toshifumi Hibi )

공동연구자( 49)

유사연구자 ( 20)※활용도순 상위 20명

'( Toshifumi Hibi )'의 연구자 점유율

'( Toshifumi Hibi )'의 발표논문(8)